Marc Bourcier

TL;DR: The role of the immune system and T-helper (Th) cells in psoriasis pathogenesis was recognized by as discussed by the authors, who found that IL-17A, the principal effector cytokine of Th17 cells, stimulates keratinocytes to produce chemokines, cytokines, and other proinflammatory mediators thereby enabling IL17A to bridge the innate and adaptive immune systems to sustain chronic inflammation.

TL;DR: Significant clinical responses to secukinumab were observed 2 weeks after a single infusion, associated with extensive clearance of cutaneous neutrophils parallel to the normalization of keratinocyte abnormalities and reduction of IL‐17‐inducible neutrophil chemoattractants; effects on numbers of T cells and CD11c‐positive dendritic cells were more delayed.

TL;DR: Most patients with Psoriasis have nail changes, and treating nail psoriasis is challenging, so it is important to know how to identify and treat these changes.

TL;DR: Etanercept demonstrated sustained effectiveness and a favorable safety profile with no cumulative toxicity for up to 4 years, representing, to the authors' knowledge, the longest published study on etanercept use in psoriasis to date.

TL;DR: A consensus statement is developed that describes two categories of psoriasis severity, while accounting for special circumstances where patients may require systemic therapy.